License and Agreements (Details)	1 Months Ended			3 Months Ended				6 Months Ended
	May 31, 2020	Jan. 31, 2020 USD ($)	Jan. 31, 2019	Jun. 30, 2021 USD ($)	Jun. 30, 2021 AUD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2020 AUD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2021 AUD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2020 AUD ($)	Dec. 31, 2020 USD ($)	Dec. 24, 2019 USD ($)	Mar. 31, 2018 USD ($)
License and Agreements (Details) [Line Items]
Assignment fee														$ 100,000
Milestone fee													$ 50,000
Common shares outstanding price percentage													1.00%
Payments of shares		$ 50,000
Accounts payable due				$ 28,000				$ 28,000				$ 59,000
Research and development expense				303,000		$ 682,000		797,000		$ 1,017,000
Pre-marketing approvals								25,000,000
Research and development costs				105,000				301,000
Interest fee								500,000
Master Services [Member]
License and Agreements (Details) [Line Items]
Assignment fee												$ 56,000
Agreement term, description			In January 2019, the Company cancelled all of the individual study contracts with ITR and entered into contracts with 11036114 Canada Inc. (initially dba VJO Non-Clinical Development and now dba Strategy Point Innovations (“SPI”)) and 11035835 Canada Inc., (dba Periscope Research) to complete additional pre-clinical research and development services in order to take advantage of eligible Canadian Tax Credits.
research and development cost				512,000		70,000		2,380,000		1,004,000
Novotech (Australia) Pty Ltd. [Member]
License and Agreements (Details) [Line Items]
Research And Development Expense				166,000	$ 216,000	65,000	$ 99,000	710,000	$ 921,000	121,000	$ 184,000
Nucleus Network Pty Ltd. [Member]
License and Agreements (Details) [Line Items]
Research And Development Expense				156,000	$ 202,000	$ 221,000	$ 335,000	344,000	$ 446,000	$ 242,000	$ 368,000
Augmenta [Member]
License and Agreements (Details) [Line Items]
Research And Development Expense				449,846				487,946
Receivable for reimbursement amount								489,221
master consultancy agreement with Novotech (Australia) Pty Ltd. [Member]
License and Agreements (Details) [Line Items]
Agreement description		to provide initial contract clinical research and development services for the Company’s drug product candidates. The accounts payable due in connection with this agreement was approximately AUD$92,000 (US$69,000) and AUD$170,000 (US$131,000) as of June 30, 2021 and December 31, 2020, respectively.
clinical trial research agreement with Nucleus Network Pty Ltd.[Member]
License and Agreements (Details) [Line Items]
Agreement description	to provide a Phase I study of one of the Company’s drug candidates, Tacrolimus. The accounts payable due in connection with this agreement was approximately AUD$3,000 (US$2,000) and AUD$51,000 (US$40,000) as of June 30, 2021 and December 31, 2020, respectively.
Master Services Agreement [Member]
License and Agreements (Details) [Line Items]
Accounts payable due				$ 5,000				$ 5,000